Fri, Nov 28, 2014, 10:50 PM EST - U.S. Markets closed early today

Recent

% | $
Quotes you view appear here for quick access.

St. Jude Medical Inc. Message Board

  • manbody93 manbody93 Mar 21, 2011 6:57 AM Flag

    ot) Blockbuster approval in 3Q11/Stock at Cash Level !!!

    LOAD UP THE MASSIVE UNDERVALUED SHARES BEFORE THE PEOPLE DISCOVER THIS SLEEPING LOW FLOAT GIANT .THIS STOCK IS TRADING BELOW CASH AND ITS CURRENTLY WAYYYY OVERSOLD = STRONG BUY AGGRESSIVE .GL

    Neurogesx has a great product called Qutenza(Neuropathic pain) which is NEW on the Market in Europe and USA since mid 2010 .Qutenza sales could reach 450++Million per year .

    NeurogesX announced plans to submit a sNDA for Qutenza in the first half of 2011 for the treatment of HIV-associated neuropathy (HIV-AN) .Qutenza, which currently has U.S. orphan drug designation and fast track status, may be eligible for six-month priority review. Qutenza has Blockbuster Potential in this new HIV indication .

    NGSX is a minimum $12+ Stock trading at a huge bargain .

    Neurogesx (NGSX)

    Market Cap: 61 M
    Cash: 57.7 M
    Price: 3.46

    Shares Out: 17.7 M
    Float : 4 M



    Dr. Juan Sanchez, an analyst at Punk Ziegel Healthcare Group, says Qutenza could be widely adopted as a treatment for chronic peripheral neuropathic pain conditions, and as such it has an opportunity to be a $300 million product in the U.S. and generate sales of $175 million in Europe. The FDA's approval of Qutenza was the first in 10 years for a prescription-strength topical treatment of pain from post-herpetic neuralgia (PHN). Neuralgia is the nerve pain that occurs with shingles. Every year about 1 million Americans develop shingles, a painful viral infection caused by reactivation of a virus that causes chickenpox.















    32e23e23e23e323e23

 
STJ
67.96+0.12(+0.18%)Nov 28 1:03 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Chevron Corporation
NYSEFri, Nov 28, 2014 1:00 PM EST
BP p.l.c.
NYSEFri, Nov 28, 2014 1:02 PM EST